hengrui glp-1 China Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) New GLP-1R agonists disclosed in

Youll have to be diligent to stave them off

Put plainly, when theres less body weight to maintain, the body does less work but it also becomes extra efficient, burning fewer calories than predicted and nudging weight back up

Her clinical lymphedema stage progressed from ISL 1 (mild lymphedema) to ISL 2 (moderate lymphedema)

GLP-1 medicines provide benefits like improved insulin sensitivity, weight management, menstrual cycle regulation, and reduced cardiovascular disease risk for women with PCOS

The process matters

In the SURMOUNT-1 trial, tirzepatide produced average weight reductions of 15.0%, 19.5%, and 20.9% at studied doses compared with 3.1% with placebo over 72 weeks